Mylan, Pfizer Settle Caduet, Lipitor Suits; Mylan May Launch Caduet Copy in 2011

Mylan Inc. Jan. 25 said it has reached two separate patent litigation settlement agreements with New York-based Pfizer Inc. over Mylan’s applications to launch generic versions of the Pfizer drugs Caduet (amlodipine besylate/atorvastatin calcium tablets) and Lipitor (atorvastatin calcium tablets).

Under the Caduet settlement agreement, pending litigation will be dismissed and Mylan may begin to market and sell a generic version of Caduet, a combination blood pressure and cholesterol drug, Nov. 30, or earlier, under certain circumstances, the Pittsburgh-based company said. Pfizer sued Mylan over its bid to launch a generic Caduet product in Delaware federal court in February 2010 ...